Drug makers and independent oncology practices slammed pharmacy benefit managers’ role in 340B contract pharmacy growth in recent public comment to the Federal Trade Commission.
Drug makers and independent oncology practices slammed pharmacy benefit managers’ role in 340B contract pharmacy growth in recent public comment to the Federal Trade Commission.
*Sign up for news summaries and alerts from 340B Report